Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration.

Aortic disease: Losartan versus atenolol in the Marfan aorta-how to treat? Nat Rev Cardiol (2015) 0.81

A Case Based Approach to Clinical Genetics of Thoracic Aortic Aneurysm/Dissection. Biomed Res Int (2016) 0.76

Aetiology and management of hereditary aortopathy. Nat Rev Cardiol (2017) 0.75

Strategies to prevent aortic complications in Marfan syndrome. J Thorac Dis (2017) 0.75

Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature (1991) 11.44

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16

Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet (1996) 7.84

Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31

The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87

The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue. Circulation (1955) 5.36

Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med (1994) 5.03

Life expectancy and causes of death in the Marfan syndrome. N Engl J Med (1972) 3.78

Lessons on the pathogenesis of aneurysm from heritable conditions. Nature (2011) 2.97

Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J (2013) 2.37

Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J (2007) 2.14

Usefulness of losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol (2013) 1.68

Medical management of Marfan syndrome. Circulation (2008) 1.44

A prospectus on the prevention of aortic rupture in the Marfan syndrome with data on survivorship without treatment. Johns Hopkins Med J (1971) 1.40

Evidence for Marfan cardiomyopathy. Eur J Heart Fail (2010) 1.35

Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations. J Cardiovasc Med (Hagerstown) (2009) 1.16

Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. Am Heart J (2013) 1.14

Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc (2013) 1.12

Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome. J Am Soc Echocardiogr (2013) 1.09

Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis (2010) 1.08

Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys-Dietz syndromes. Hum Mutat (2011) 1.05

The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. Int J Cardiol (2011) 1.04

A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials (2013) 1.02

[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. Rev Esp Cardiol (2011) 0.96

Epidemiological profile of Marfan syndrome in a general population: a national database study. Mayo Clin Proc (2014) 0.89

Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome. Heart (2013) 0.88

Mitral valve disease in Marfan syndrome and related disorders. J Cardiovasc Transl Res (2011) 0.84

The expanding cardiovascular phenotype of Marfan syndrome. Eur J Echocardiogr (2008) 0.83

Clinical utility gene card for: Marfan syndrome type 1 and related phenotypes [FBN1]. Eur J Hum Genet (2010) 0.80

Cardiovascular characteristics in Marfan syndrome and their relation to the genotype. Verh K Acad Geneeskd Belg (2009) 0.80

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet (2014) 10.26

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol (2016) 0.90

The SMAD-binding domain of SKI: a hotspot for de novo mutations causing Shprintzen-Goldberg syndrome. Eur J Hum Genet (2014) 0.84

Effect of CPAP on Cardiac Function in Minimally Symptomatic Patients with OSA: Results from a Subset of the MOSAIC Randomized Trial. J Clin Sleep Med (2015) 0.80

Cervical artery dissections and type A aortic dissection in a family with a novel missense COL3A1 mutation of vascular type Ehlers-Danlos syndrome. Eur J Med Genet (2015) 0.78

Laparoscopic Surgery Requiring Abdominal Insufflation in Patients With Congenital Heart Disease. J Cardiothorac Vasc Anesth (2021) 0.75